Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.

[1]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[2]  B. Zinman,et al.  The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics , 2017, American Journal of Nephrology.

[3]  G. Laverman,et al.  The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients , 2017, Diabetes, obesity & metabolism.

[4]  Y. Terauchi,et al.  Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial , 2017, Diabetes, obesity & metabolism.

[5]  S. Kaspers,et al.  Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials , 2017, Advances in Therapy.

[6]  M. Davies,et al.  Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone , 2017, Diabetes, obesity & metabolism.

[7]  T. Kadowaki,et al.  Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial , 2017, Diabetes, obesity & metabolism.

[8]  M. Jardine,et al.  Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. , 2017, Journal of the American Society of Nephrology : JASN.

[9]  P. Baglioni,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. , 2017, The New England journal of medicine.

[10]  M. Monami,et al.  Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials , 2017, Acta Diabetologica.

[11]  E. Søfteland,et al.  Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial , 2016, Diabetes Care.

[12]  É. Hardy,et al.  Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[13]  C. Mathieu,et al.  Efficacy and safety of triple therapy with dapagliflozin add‐on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[14]  T. Mansfield,et al.  Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial , 2016, Journal of diabetes.

[15]  Jindan Wu,et al.  Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus , 2016, Journal of diabetes research.

[16]  H. Ishihara,et al.  Efficacy and safety of ipragliflozin as add‐on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi‐centre, randomized, placebo‐controlled, double‐blind study , 2016, Diabetes, obesity & metabolism.

[17]  S. Hadjadj,et al.  Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes , 2016, Diabetes Care.

[18]  N. Inagaki,et al.  Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus , 2016, Cardiovascular Diabetology.

[19]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[20]  H. Rodbard,et al.  Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin , 2016, Diabetes, obesity & metabolism.

[21]  V. Perkovic,et al.  Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. , 2016, The lancet. Diabetes & endocrinology.

[22]  T. Mansfield,et al.  Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade , 2016, Blood pressure.

[23]  T. Mansfield,et al.  Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. , 2016, The lancet. Diabetes & endocrinology.

[24]  E. Araki,et al.  Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16‐week double‐blind treatment period , 2016, Journal of diabetes investigation.

[25]  J. Rosenstock,et al.  Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes , 2016, Diabetes Care.

[26]  R. Townsend,et al.  Reductions in Mean 24‐Hour Ambulatory Blood Pressure After 6‐Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension , 2016, Journal of clinical hypertension.

[27]  B. Cha,et al.  Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial , 2015, Journal of diabetes investigation.

[28]  M. Haneda,et al.  Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. , 2016, Clinical therapeutics.

[29]  N. Watts,et al.  Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. , 2016, The Journal of clinical endocrinology and metabolism.

[30]  M. Roden,et al.  Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial , 2015, Cardiovascular Diabetology.

[31]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[32]  J. Rosenstock,et al.  Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors , 2015, Diabetes Care.

[33]  G. Meininger,et al.  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program , 2015, Diabetes Care.

[34]  Simeon I. Taylor,et al.  Possible adverse effects of SGLT2 inhibitors on bone. , 2015, The lancet. Diabetes & endocrinology.

[35]  G. Bakris,et al.  Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease , 2014, Diabetes, obesity & metabolism.

[36]  Lawrence A. Leiter,et al.  Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study , 2014, Diabetes Care.

[37]  A. Mithal,et al.  Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.

[38]  D. Kohan,et al.  Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control , 2013, Kidney international.

[39]  D. Matthews,et al.  Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes , 2013, Annals of Internal Medicine.

[40]  A. Avogaro,et al.  Treating diabetes today with gliclazide MR: a matter of numbers , 2012, Diabetes, obesity & metabolism.

[41]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[42]  M. Symons,et al.  Hazard rate ratio and prospective epidemiological studies. , 2002, Journal of clinical epidemiology.

[43]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[44]  A. Abramson.  Bone disturbances in injuries to the spinal cord and cauda equina (paraplegia) their prevention by ambulation. , 1948, The Journal of bone and joint surgery. American volume.